ABSTRACT Aim: This study evaluated the long-term effects of enteral glutamine supplementation on neurodevelopmental outcomes of a Dutch cohort of very preterm children at 13 years of age.
INTRODUCTION
Children born very preterm are highly susceptible to infection and inflammation due to immaturity of their immune system and gastrointestinal tract (1, 2) . Clear evidence has been published that serious neonatal infections are associated with impaired brain development and poor neurodevelopmental outcomes in very preterm children (3) . One factor that may enhance gut maturation and immune function is glutamine, which is a conditionally essential amino acid that serves as an important source of energy for enterocytes and immune cells (4) . During catabolic states, plasma levels of glutamine are low, which may impair mucosal integrity and immune function (4, 5) . Very preterm children are particularly prone to glutamine depletion, because preterm delivery interrupts the high placental glutamine supply, parenteral feeding does not contain glutamine and feeding intolerance impedes full enteral feeding.
Our previous study showed that enteral glutamine supplementation in very preterm children positively affected feeding tolerance and infectious morbidity (6) and had a positive effect on brain development at eight years of age Abbreviations IQ, Intelligence quotient; RCT, Randomised controlled trial.
Key notes
We evaluated the long-term effects of enteral glutamine supplementation on the neurodevelopmental outcomes of very preterm children. Between 2001 and 2003, the infants received either glutamine-or alanine-supplemented enteral nutrition during the first month of life, and 61 were followed up as teenagers. Our study provided no evidence that enteral glutamine had any beneficial or adverse effects on the children's motor, neurocognitive, academic and behavioural outcomes at 13 years of age.
(7). More specifically, enteral glutamine supplementation was associated with increased white matter, hippocampus and brainstem volumes, which were mediated by the number of neonatal infections. Given the increase in regional brain volumes, an improvement of neurocognitive functioning might have been expected (8) . However, no differences were found in the motor, cognitive and behavioural outcomes between the glutamine-supplemented and control groups at eight years of age (9) . Brain development is a dynamic process with significant changes occurring in the period between late childhood and early adolescence (10) . White matter development, which is to a large extent related to neurocognitive outcomes in very preterm children (11) , is characterised by a linear increase with age (12) . This could imply that the differences found in brain volume between the glutamine-supplemented and control groups at eight years of age may become more pronounced with increasing age. This, in turn, could be associated with neurocognitive differences between the groups that were not apparent during childhood. This study aimed to re-evaluate the effect of enteral glutamine supplementation on motor, neurocognitive, academic and behavioural outcomes in the same cohort of very preterm children at 13 years of age. These domains have previously been shown to represent core deficits in very preterm children (13) . Based on the earlier reported decrease in infectious morbidity and increase in brain volumes at the age of eight, it was hypothesised that enteral glutamine supplementation would be associated with better neurodevelopmental outcomes during adolescence. To our knowledge, this was the first study on the effects of enteral glutamine supplementation on long-term neurodevelopmental outcomes.
METHODS

Participants
This study was the latest follow-up phase of a birth cohort in the Netherlands, and it took place when the children reached 13 years of age. Between September 2001 and July 2003, we enrolled 102 infants born with a gestational age of less than 32 weeks and, or, a birth weight of below 1500 g to take part in a randomised controlled trial (RCT) to investigate the effects of glutamine-enriched enteral nutrition (14) . They had all been admitted to the level three neonatal intensive care unit of the VU University Medical Centre in Amsterdam within 48 hours of birth; the study infants were randomly allocated to receive either glutamine-or alanine-supplemented enteral nutrition, which were administered in increasing doses between day 3 and 30 of life. The maximum dose in the glutamine-supplemented group was 0.3 g/kg/day. Further details on the intervention, inclusion and randomisation are described in the study protocol (registry number: ISRCTN73254583) (14) . At one year of age, 88 (86%) of the 102 infants were alive and eligible for follow-up. At 7-8 years of age, 64 (73%) of the 88 eligible children at one year were assessed with regard to their neurodevelopmental outcomes (9) . At the age of 13, we assessed 61 children: 29 in the glutaminesupplemented group and 32 in the control group. A complete overview of the inclusion from birth to the 13-year follow-up is depicted in Figure 1 .
Motor, neurocognitive, academic and behavioural measures The Movement Assessment Battery for Children, second edition, (15) served as a measure of motor abilities. This battery consists of eight tests covering three areas of motor function: manual dexterity, ball skills and static and dynamic balance. For this study, children were assessed with the tests suitable for subjects aged 11-16 years. Raw total scores were used in the analyses.
Intellectual capacities were assessed using a short form of the Wechsler Intelligence Scale for Children, third edition (16), using the vocabulary and block design subtests to estimate their full-scale intelligence quotient (IQ). This short form has excellent reliability (r = 0.91) and correlates strongly (r > 0.90) with full-scale IQ (17) .
The Attention Network Task (18) was used to assess alerting, orienting and executive attention. Children were presented with a target stimulus consisting of an arrow pointing left or right. The target stimulus was flanked by four arrows pointing in either the same direction as the target stimulus in the congruent condition or the opposite direction in the incongruent condition. Stimuli were preceded by three types of warning cues: a central cue in the middle of the screen, a spatial cue indicating the position of the upcoming target or no cue. Trials were randomly presented in four blocks of 48 trials, preceded by a practice block of 12 trials. Indices of network efficiency were obtained by computing differences in the mean reaction times between the conditions: no cue-centre cue for alerting, centre cue-spatial cue for orienting and incongruentcongruent for executive attention.
To measure visuospatial working memory, an adapted version of the spatial span task developed by Nutley et al. (19) was used. Stimuli, in the form of yellow dots, were presented in a 4 9 4 grid in sequential order on a touch screen. Participants were required to reproduce sequences in the same and reverse order by tapping the locations on the touch screen. Trial difficulty was determined by the length of the sequence, path crossing and the distance between stimuli. The task was terminated after two incorrect trials with the same difficulty level. The product of the highest difficulty level reached, and the number of correctly reproduced trials for each condition was used as a dependent variable in the analyses (19) .
Reading comprehension, spelling and arithmetic were assessed using a battery of standardised tests developed by the National Institute for Educational Measurement (20) , which are used to measure children's academic skills and progression from grades one to six -which cover the ages of 6-12 -in 90% of the primary schools in the Netherlands. This study used the most recent test scores of each participant, which were the grade six test scores for most participants. For each academic domain, the raw scores were converted to a standardised score on a unidimensional continuum, which allows to compare the scores of different tests taken at different time points within, and between, participants.
The children's behaviour was rated by their parents and teachers using the Child Behaviour Checklist and Teacher Report Form, respectively (21) . Raw scores for internalising and externalising behaviour were used in the analyses. The Strengths and Weaknesses of ADHD Symptoms and Normal Behaviour (22) was used as a parent-and teacher-rated measure of attentional problems. This questionnaire was developed to capture variance at the symptomatic, as well as the adaptive, ends of the attention dimension. Behaviour was rated on a seven-point Likert scale, ranging from À3 (far above average) to +3 (far below average) when anchored to average behaviour (22) . Scientific and Ethical Review Board. Informed consent was obtained from both the parents and children. Children visited the university with their parents to complete the test battery. The tests were individually administered by trained testers, who were blind to the group allocation, using standardised instructions. Parents filled in questionnaires during their visit. Teachers were contacted with the written consent of both the children and parents to provide academic performance data and to fill in questionnaires about the child's behaviour and functioning.
Statistical analyses
Analyses were performed using IBM SPSS Statistics 23.0 (IBM Corp., Armonk, NY, USA). The amount of missing outcome data ranged from 1.8 to 10.9%. Multiple imputation with 25 imputations was applied. Groups were compared with demographic and perinatal factors using the two-tailed unpaired t-test, chi-square test or Fisher's exact test as appropriate. The effects of enteral glutamine supplementation were tested with univariate analyses of variance. Alpha levels were set at 0.05. Non-normally distributed variables were log-transformed, and Welch 0 s adjusted F statistic was used in cases of violation of the homogeneity assumption. The effect of enteral glutamine supplementation on outcomes was examined in a crude model and in a model that was adjusted for confounders. Potential confounders were selected if p < 0.20 or their inclusion resulted in ≥10% change in the estimate of glutamine (23) . The factors we considered were as follows: age, sex, parental education, gestational age, birth weight, small for gestational age, Caesarean section, multiple birth, bronchopulmonary dysplasia, intraventricular haemorrhage grade I/II, intraventricular haemorrhage grade III/IV, periventricular leukomalacia, patent ductus arteriosus and retinopathy of prematurity. Starting off with the full model with all potential confounders included, we searched for the most parsimonious model using backward elimination. The effect size measures of Cohen's d and phi were interpreted as follows: d = 0.20 and / = 0.10 were small effects, d = 0.50 and / = 0.30 were medium effects, and d = 0.80 and / = 0.50 were large effects (24) .
RESULTS
A total of 61 children with a mean age of 13.30 years, and standard deviation (SD) of 0.29 years, contributed data to this study, representing 69% of those who were alive and eligible at the age of one year. The full battery of neurodevelopmental tests and questionnaires was completed by 55 children and parents. The remaining six children and parents only filled out the questionnaires that were part of the test battery. Participants and nonparticipants were highly similar in terms of perinatal characteristics (p = 0.07-1.00), except for a significantly higher incidence of IVH grade I/II among the nonparticipants (p = 0.001). This difference was true for both conditions of the intervention (data available from author).
Demographic and perinatal characteristics of the glutamine-supplemented group and the preterm control group are presented in Table 1 . There were no significant group differences in any of these characteristics. Previous followups showed significantly lower rates of serious neonatal infections in the glutamine-supplemented group compared to the controls (9, 25) . This difference did not reach statistical significance in this study sample (p = 0.10).
The motor, neurocognitive, academic and behavioural outcomes of the glutamine-supplemented preterm group and the preterm control group are shown in Table 2 . Both the crude analyses and the analyses that were adjusted for confounding factors showed highly comparable performances in both groups with regard to the outcome measures. No differences were found in motor, cognitive and academic performances between the glutamine-supplemented and control groups. There was a significant difference in visuospatial working memory forward span between the groups, shown by both the crude model and the model adjusted for confounders (Table 2 ). Children in the control group outperformed children in the glutaminesupplemented group. No difference between groups was found for backward span. Internalising and externalising behaviour problems, as rated by parents and teachers, were not significantly different between the two groups. No difference between the groups was found in teacher-rated attention skills. Parent-rated attention skills were not different based on the crude model, but after covariate 4 (14) 3 (11) ROP, number (%) 2 (7) 2 ( adjustment, scores were significantly higher in the control group.
DISCUSSION
This long-term follow-up study at 13 years of age revealed that very preterm children in the glutamine-supplemented group showed similar performance on measures of motor, neurocognitive, academic and behavioural outcomes to very preterm children in the control group. This suggests that enteral glutamine supplementation in very preterm children during the first month of life has neither beneficial nor adverse effects on these outcomes at 13 years of age. At eight years of age, an increase in white matter, hippocampus and brain stem volume was found in the glutamine-supplemented group compared to the control group. This effect was mediated by the number of neonatal infections (7) . The findings on functional outcomes of the current follow-up study are in line with the functional findings of the follow-up of the same cohort at eight years of age (9) . This indicates that the lowered incidence of neonatal infection and the increased regional brain volumes in the glutamine-supplemented group did not translate into significantly improved functional outcomes in these children. Nutritional deficiencies, infection and inflammation are important risk factors for poor neurodevelopmental outcomes in very preterm children (3, 26) . However, the eventual outcomes are determined by complex interactions of genetic and environmental factors. For example, nutritional deficiencies were shown to have a larger impact on neurocognitive outcomes in children growing up in less stimulating environments than children in more stimulating environments (27) . It is conceivable that the positive effects of glutamine on infection and brain development did not alter long-term neurocognitive outcomes because these effects are either nullified by other factors or only expressed under certain conditions.
The difference between the glutamine-supplemented group and the control group in spatial span forward was an unexpected finding. No differences between the two groups were found in backward spatial span. For verbal digit span tasks, it is well established that recall in reverse order is more difficult than in the same order (28). This is not true for spatial span. Studies comparing spatial span performance showed no differences between the forward and backward condition (29, 30) . In line with these studies, our results showed similar performance on the forward and backward conditions in the glutamine group, while in the control group performance on the forward condition was significantly better than on the backward condition. This suggests that given the backward spatial span, the forward spatial span of the control group might be unusually large. Therefore, we could argue that the difference between the glutamine-supplemented and control groups in forward spatial span resulted from an unusually good performance in the control group, rather than an unexpectedly poor performance in the glutamine group. Long-term follow-up studies of RCTs of nutritional interventions are scarce, but necessary to establish the effects and risks of these interventions. The current study is one of the few RCTs on nutrition in preterm children with a long-term follow-up. Attrition is a common and inherent problem of long-term follow-up studies, and this also limited the current study. It affects statistical power and the generalisability of the results. Due to our small sample size, there is an increased probability of missing potentially important long-term effects of glutamine supplementation. Moreover, the relatively small sample size limited the possibility to explore if there were certain characteristics or circumstances under which glutamine supplementation would be particularly beneficial. Nevertheless, our study had a satisfactory follow-up rate, and there was no evidence for selective loss to follow-up. Therefore, despite its limitations, we feel that the current study makes a valuable contribution to the search for optimal feeding strategies of very preterm infants.
CONCLUSION
Our study provided no evidence for beneficial or adverse effects of enteral glutamine supplementation in very preterm children during the first month of life on motor, neurocognitive, academic and behavioural outcomes at 13 years of age. This was the first study on the effects of enteral glutamine supplementation on long-term neurodevelopmental outcomes. The positive effects of enteral glutamine supplementation on neonatal infections, time to full enteral feeding and brain volume are promising and of potential clinical importance (6, 7) . Future studies may clarify under which conditions enteral glutamine supplementation would be most beneficial and further investigate the optimal dosage and duration of enteral glutamine supplementation. Furthermore, it would be of interest to study the neuroprotective effects of glutamine in combination with other nutritional interventions that could be potentially beneficial to brain development (26) .
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